 "Supriya Lifescience")
Supriya Life Sciences is strengthening its presence in regulated global markets with a manufacturing facility in Ambernath, around 50 km from Mumbai, as the company lines up capacity expansion to support long-term growth across active pharma ingredients (APIs) and contract manufacturing.
The ₹165 crore facility has been set up as a dedicated plant for finished formulations, catering primarily to contract-manufacturing requirements of customers in regulated markets such as Europe, Latin America, and North America.
The company said the site had received approval from the World Health Organization on “good manufacturing practices”, while regulatory clearances from the European Union and the United States (US) Food and Drug Administration are in process.
The Mumbai-based pharma company in FY25 posted revenues of ₹706 crore in FY25, along with a profit of ₹187.9 crore.
Commenting on the expansion, Managing Director Saloni Satish Wagh said: “Finished formulations and contract manufacturing are a natural extension of our API capabilities. With this facility, we are building a platform that allows us to partner more closely with customers in regulated geographies while maintaining our focus on quality, backward integration and margins.”
Wagh added while ramping up capacity would be gradual due to regulatory timelines, the company remained confident of achieving optimal utilisation over the medium term.
Commercial revenues from the Ambernath facility are expected to begin in the fourth quarter this financial year, following pilot production and validation activities.
The plant houses multiple manufacturing lines, including liquid inhalation, tablets, capsules and injectables, with phase one commencing with the liquid inhalation line. The inhalation line has a capacity of around 5 million bottles annually, while the tablets and capsules line can produce up to 1 billion units per year.
The company indicated the optimal utilisation of the new formulations facility was likely to be achieved only over the next three to four years. Full utilisation is expected around FY29.
Supriya Life Sciences continues to scale up its API operations alongside formulations. The company’s API capacity stands at about 950 kilolitres following the addition of a new module and debottlenecking initiatives. Capacity utilisation at the API plant is around 70 per cent, with full utilisation expected by FY28.
The company reiterated its revenue growth guidance of over 20 per cent annually over the next few years, factoring in contributions from both the API and finished formulations businesses. Supriya Life Sciences derives nearly 85 per cent of its revenues from exports, with Europe accounting for about 45 per cent of revenues, followed by Latin America with around 20 per cent.
North America contributes 4-5 per cent while the balance comes from Southeast Asia and other regions.
While the domestic market accounts for about 15 per cent of revenues, a significant portion of this is linked to multinational customers, whose finished formulations are exported to regulated markets. The company said it intended to remain export-oriented, citing better margins and long-term stability in regulated markets than domestic or semi-regulated geographies.
As part of its medium-term expansion plans, Supriya Life Sciences has acquired a land parcel of 25-30 acres in Patalganga for a greenfield manufacturing site. Work is expected to begin in FY27, with capacity addition planned in a phased manner.
The company is yet to finalise whether the new site will focus on APIs or finished formulations.
The company is planning to introduce three to four APIs each year, focusing on niche and complex molecules with full backward integration. The company is also expanding its offers on contract manufacturing and design and working on formulations for regulated markets.
Spending on research & development currently stands at 1.5-1.8 per cent of revenues and is expected to rise to about 2 per cent over the next two years.
Commenting on the regulatory environment, the company said global regulators were increasingly emphasising continuous compliance on good manufacturing practices, with shorter-notice inspections and tighter impurity norms.
However, its backward integration, regulatory preparedness and focus on niche products position it well to navigate pricing pressures and benefit from the China-plus-one sourcing shift, it said.
